CRISPR Therapeutics AG
CRSP
$54.79
$0.46620.86%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 892.00K | 865.00K | 35.69M | 602.00K | 517.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 892.00K | 865.00K | 35.69M | 602.00K | 517.00K |
| Cost of Revenue | 115.05M | 129.99M | 82.16M | 93.31M | 132.30M |
| Gross Profit | -114.16M | -129.13M | -46.46M | -92.71M | -131.78M |
| SG&A Expenses | 18.92M | 19.30M | 18.12M | 17.42M | 19.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 133.96M | 149.29M | 100.28M | 110.73M | 151.78M |
| Operating Income | -133.07M | -148.42M | -64.59M | -110.13M | -151.26M |
| Income Before Tax | -207.26M | -134.89M | -36.61M | -85.07M | -125.12M |
| Income Tax Expenses | 1.29M | 1.11M | 700.00K | 876.00K | 1.29M |
| Earnings from Continuing Operations | -208.55M | -136.00M | -37.31M | -85.94M | -126.41M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -208.55M | -136.00M | -37.31M | -85.94M | -126.41M |
| EBIT | -133.07M | -148.42M | -64.59M | -110.13M | -151.26M |
| EBITDA | -128.42M | -143.69M | -59.75M | -105.39M | -146.42M |
| EPS Basic | -2.40 | -1.58 | -0.44 | -1.01 | -1.49 |
| Normalized Basic EPS | -0.80 | -0.98 | -0.27 | -0.62 | -0.92 |
| EPS Diluted | -2.40 | -1.58 | -0.44 | -1.01 | -1.49 |
| Normalized Diluted EPS | -0.80 | -0.98 | -0.27 | -0.62 | -0.92 |
| Average Basic Shares Outstanding | 87.07M | 85.94M | 85.46M | 85.23M | 84.92M |
| Average Diluted Shares Outstanding | 87.07M | 85.94M | 85.46M | 85.23M | 84.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |